Background: Conditioned pain modulation (CPM) is widely used to measure endogenous analgesia, and a recent study indicated that drugs that act on endogenous analgesia are more effective in individuals with lower CPM. Recent animal studies have indicated that pregabalin activates endogenous analgesia by stimulating the descending pain inhibitory system. The present study examined whether the analgesic effect of pregabalin is greater in individuals with lower original endogenous analgesia using CPM. Methods: Fifty-nine healthy subjects were randomly assigned to either a pregabalin group or a placebo group, and 50 of them completed the study. CPM was measured before and after pregabalin or placebo administration. The correlation of initial CPM to change in CPM was compared between the pregabalin and placebo groups. Results: Initial CPM was significantly correlated with the change in CPM in the pregabalin group (r = À0.73, p < 0.0001) but not in the placebo group (p = 0.56) (difference in correlation coefficients between groups; p = 0.004). Furthermore, the initial CPM significantly affected the change in CPM in the pregabalin group but not in the placebo group (pregabalin group: adj R 2 = 0.51, p < 0.001, y = À0.54x + 2.98; placebo group: p = 0.56, significant difference in regression slopes; p = 0.015). These results indicate that pregabalin has a higher endogenous analgesic effect in individuals with lower original endogenous analgesia. Significance: The analgesic effect of pregabalin depends on the original endogenous analgesia status. Its effect on conditioned pain modulation (CPM) was stronger for subjects with lower original endogenous analgesia, suggesting that the mechanism of pregabalin involves the improvement of endogenous analgesia.
Introduction
Pregabalin and gabapentin are frequently used for management of chronic pain. Their analgesic mechanism is different from that of conventional analgesic drugs because they specifically bind to the voltagedependent a2d calcium channel with high affinity (Taylor, 2009) , and they have demonstrated clinical efficacy for epilepsy and anxiety disorders in addition to neuropathic pain (Richter et al., 2005; Tassone et al., 2007) . Although the exact analgesic mechanisms are unclear, one of the suggested mechanisms for their anti-hypersensitivity effect in neuropathic pain is the stimulation of the descending inhibitory system (Kukkar et al., 2013) , which is one of the mechanisms underlying endogenous analgesia. In particular, gabapentin and pregabalin are thought to activate noradrenergic neurons by reducing presynaptic GABAergic activity in the locus coeruleus, thereby increasing noradrenaline release, which subsequently inhibits pain transmission via spinal a 2 -adrenorecepters (Tanabe et al., 2008; Kukkar et al., 2013) .
Conditioned pain modulation (CPM) is psychophysical paradigm in which noxious stimulation induces analgesia in other sites of the body, and it is used to describe the effect of endogenous analgesia (Yarnitsky, 2010) . Some diseases with chronic pain, such as irritable bowel syndrome, temporomandibular disorder, tension type headache, fibromyalgia, trigeminal neuralgia, and chronic fatigue syndrome, are characterized by reduced efficiency of CPM (Yarnitsky, 2010) , indicating a critical role for endogenous analgesia in some chronic pain states. In a study where diabetic neuropathic pain was treated with duloxetine, a serotonin and noradrenalin reuptake inhibitor (SNRI) known to stimulate descending noradrenergic inhibition (Hoshino et al., 2015) , drug efficacy was shown to be significantly correlated with initial CPM, and higher drug efficacy was observed in patients with lower initial CPM (Yarnitsky et al., 2012) . This result led us to consider that pregabalin also would show higher efficacy in subjects with lower initial CPM. In the present study, we hypothesized that pregabalin would enhance endogenous analgesia, especially in subjects who originally had low levels of endogenous analgesia. To test this hypothesis, we examined the relationship between the initial CPM and drug efficacy measured as the change in CPM in healthy human volunteers. The influence of initial CPM on drug efficacy (represented by the change in CPM) was also compared between pregabalin and placebo to examine whether or not the analgesic effect of pregabalin depends on the original degree of endogenous analgesia.
Methods

Subjects
This study was approved by the IRB of Gunma University Graduate School of Medicine (approved No. 1009) in Maebashi, Japan. The study was conducted in accordance with institutional ethical provisions and the Declaration of Helsinki.
Subjects were recruited from July 2013 to February 2015. Fifty-nine healthy subjects (30 men and 29 women) who provided written informed consent participated in this study. Inclusion criteria were age between 20 and 55 years. Exclusion criteria were chronic pain, tissue injury at the stimulation sites, and inability to withstand the heat stimulus used in this study. Subjects were instructed not to eat for 1.5 h before the experiment out of consideration of potential effects on drug absorption speed.
Study design
This study was a double-blinded placebo-controlled study. All experiments were conducted by one person who was not involved in the drug randomization. Subjects were randomly assigned to either the pregabalin group or the placebo group by permuted block randomization method performed by a person who was not involved in data collection. All experiments were conducted in the same room in the outpatient ward of Gunma University Hospital during daytime (8:00-18:00). The general study design is shown in Fig. 1A . Because it takes approximately 1.5 h before and approximately 3 h after administration of study drug in the study session, the study drug was administered from 9:30 to 15:00. Considering the influence of hand dominance on pain response ( € Ozcan et al., 2004) , we decided the stimulation side based on hand dominance. The dominant forearm was used only for measurement of CPM, and different sites in the non-dominant forearm were used in the training phase, measurement of Pain60, and measurement of thermal pain threshold to avoid sensitization. The thermal pain threshold was measured after the measurement of mechanical pain thresholds to keep the forearm away from heat stimulation for at least 10 min. To confirm the safety of the subjects, the occurrence of adverse effects was examined at the end of study.
Training phase
Subjects were trained to be familiar with rating pain intensity and pain thresholds. First, they immersed their non-dominant hand up to the wrist in 46.5°C hot water (water bath; Personal-11, temperature controller; thermo minder, Titec, Tokyo, Japan) for 30 s. They rated the pain intensity using a numerical pain scale (NPS) (from 0 = no pain to 100 = the worst pain imaginable).
Second, a series of heat stimuli (45, 46, and 47°C) was applied to the non-dominant volar forearm using a thermode, which was a 30 9 30 mm thermal stimulator probe (Pathway Model ATS, Medoc, Ramat Yishai, Israel). The heat stimulation lasted for 7 s. The temperature transitioned from the baseline temperature (32°C) to the stimulation temperature over a 2-s period. The heat stimuli were provided three times in different orders of temperature with a 1-min inter-stimulus interval. The subjects rated the pain intensity using the NPS at the end of each stimulation.
Third, the mechanical and thermal pain thresholds of the subjects were evaluated. For the mechanical pain threshold, algometer (Somedic AB, Stockholm, Sweden) or pressure applicator (IITC Life Science: CA, USA) probes were applied to the subjects until the moment they began to feel pain. Pressure was applied to the fingernail of the middle finger in the non-dominant hand using the algometer (probe surface area; 1 cm 2 , pressure application rate; approximately 30 kPa/s) without touching the nail fold. Pressure was applied to the thenar area of the non-dominant hand using the pressure applicator (pressure application rate; approximately 10 g/s). For the thermal pain threshold, the baseline temperature of the thermode was set to 32°C with a rate of increase in 1°C/s, and the thermode was applied to the non-dominant volar forearm. The subjects stopped the heat stimulus by pressing a button at the moment when they began to feel pain.
Determination of Pain60
After the training phase, we determined the temperature to use for the test stimulus, Pain60 (i.e. the stimulus producing a score of 60 on the NPS scale), based on a previous report (Fig. 2) . Heat stimuli were applied to the non-dominant volar forearm as described above for the training phase. The average NPS was calculated for each temperature. The temperature that resulted in the NPS closest to 60 was determined as the temperature for Pain60. If all of the average NPSs were higher or lower than 60, an additional series of heat stimuli (43, 44, and 45°C or 46, 47, and 48°C, respectively) was applied and the calculations were repeated.
Determination of pain thresholds and CPM
Pain thresholds and conditioned pain modulation (CPM) were measured twice, before and after administration of the study drug (pregabalin or placebo). Post-administration evaluation was started 2 h after administration.
Measurement of pain thresholds in response to thermal and mechanical stimuli
The mechanical pain threshold and the thermal pain threshold were examined as described above for the training phase.
Measurement of CPM
CPM was evaluated based on the method used in a previous study (Yarnitsky et al., 2012; Fig. 1B) . The Figure 1 (A) General study design. First, subjects were trained to rate pain intensity and pain thresholds. Subsequently, the temperature for Pain60 was determined. Then, conditioned pain modulation (CPM) and pain thresholds were measured twice, before and after administration of pregabalin or placebo. The post-administration measurement session was started 2 h after administration of pregabalin or placebo. (B) Flowchart showing the process for measurement of CPM.
Pain60 temperature was used as the test stimulus and 46.5°C hot water was used as the conditioning stimulus. The test stimulus was applied for 30 s to the dominant volar forearm (baseline test stimulus). After 30 min, subjects inserted their non-dominant hand into 46.5°C hot water, i.e. the conditioning stimulus, for 60 s. In the last 30 s of the 60-s conditioned stimulus, a test stimulus was applied to the dominant volar forearm (conditioned test stimulus). The subjects rated the pain intensity using the NPS at 10, 20, and 30 s after each test stimulus and conditioning stimulus was initiated. CPM was calculated as the difference in average NPS scores between test stimuli only and test stimuli with conditioning stimuli (conditioned test stimulus), i.e. CPM = NPS (test stimulus) À NPS (conditioned test stimulus). CPM was examined before (initial CPM) and 2 h after (post-CPM) the administration of study drugs. The change in CPM was calculated as the difference between the initial CPM and the post-CPM, i.e. change in CPM = post-CPM À initial CPM. A higher (lower) initial CPM represents higher (lower) original endogenous analgesia and a higher (lower) change in CPM represents greater (lesser) improvement of endogenous analgesia by drug administration.
Drugs
The study drugs were prepared in the Department of Clinical Pharmacology at Gunma University Graduate School of Medicine. Lactose as a placebo or pregabalin (Lyrica â , Pfizer, 150mg) was enclosed in the same type of capsule such that the placebo and experimental capsules could not be distinguished from each other. Similarly, the placebo and pregabalin capsules were packed in the same type of package, and the packages were numbered randomly.
Statistical analysis
For the statistical analysis, VassarStats (Significance of the Difference Between Two Correlation Coefficients, http://vassarstats.net/rdiff.html) was used for comparison of correlation coefficients, and Sigmaplot version 12.5 was used for other analyses. The coefficients for correlation between the initial CPM and change in CPM were compared between the pregabalin and placebo group. The influence of initial CPM on drug efficacy was evaluated by linear regression analysis using the initial CPM as the independent variable and the change in CPM as the dependent variable, and the slopes of the linear regression lines were compared. Furthermore, to differentiate the analgesic effect of pregabalin from the effect of the regression to the mean, we conducted additional scatterplot and regression line analyses similar to those previously described by Barnett et al. (2005) . Because CPM is calculated from the NPS of the test stimulus and conditioned test stimulus, to examine the regression to the mean, the change in NPS, i.e. pre-administration NPS (initial NPS) -postadministration NPS (post-NPS), was used as the dependent variable and the initial NPS was used as the independent variable for the test stimulus and conditioned test stimulus. We also compared the change in pain threshold before and after drug administration between groups, for each stimulus (i.e. thermal and mechanical), to investigate whether pregabalin had an antinociceptive effect. Statistical analysis using t-test was performed to compare the threshold changes between groups.
Sample size was determined using G*power 3 (Faul et al., 2007) (one-tailed, alpha = 0.05, power = 0.8, r1 = 0 as control group, r2 = 0.628 as pregabalin group, N1/N2 = 1). The correlation coefficient for the pregabalin group was predicted according to the results of Yarnitsky et al. (2012) . The sample size was calculated as 26 for each group. Considering the number of expected dropouts, we recruited 59 subjects.
Results
Subjects
Fifty-nine subjects (30 male and 29 female, 24.3 AE 4.8 years of age) were enrolled in this study. Nine subjects (5 from the pregabalin group and 4 from the placebo group) dropped out from the study because of failure to determine Pain60; thus, 50 subjects (24 in the pregabalin group and 26 in the placebo group) completed the study (Fig. 3) . Detailed data for the subjects who completed the test and the adverse effects data are shown in Table 1 and data on pain thresholds are shown in Table 2 . Among the recruited subjects, none had renal disease.
Effect of pregabalin and initial CPM
Initial CPM was significantly correlated with the change in CPM in the pregabalin group (r = À0.73, p < 0.0001) but not in the placebo group (p = 0.56) (difference in correlation coefficients between groups; p = 0.004). The regression slopes were significantly different between the pregabalin and placebo groups (p = 0.015). The regression analysis revealed that the initial CPM significantly affected the change in CPM in the pregabalin group but not in the placebo group (pregabalin group: adj R 2 = 0.51, p < 0.001, y = À0.54x + 2.98; placebo group: p = 0.56) (Fig. 4) . In subjects with a higher initial CPM, the change in CPM tended to be negative (initial CPM > post-CPM), and in subjects with a lower initial CPM, the change in CPM tended to be positive (initial CPM < post-CPM). This result indicates that pregabalin improved endogenous analgesia in individuals with lower original endogenous analgesia, but the placebo did not. Table 2 shows CPM data.
Effect of pregabalin on the response to the test stimulus and conditioned test stimulus
To differentiate the analgesic effect of pregabalin from the effect of regression to the mean, a scatterplot and regression lines, using the change in NPS as the dependent variable and the initial NPS as the independent variable, were prepared to compare the pregabalin and placebo groups for the test stimulus and conditioned test stimulus. Nine subjects (five from the pregabalin group and four from the placebo group) dropped out from the study because of failure to determine Pain60, and 50 subjects (24 in the pregabalin group and 26 in the placebo group) completed the study. The detailed data for the subjects who completed the test and the data for adverse effects are shown.
In response to the test stimulus, the change in NPS tended to be positive (initial NPS > post-NPS) in subjects with a higher initial NPS and negative (initial NPS < post-NPS) in subjects with lower initial NPS in both the pregabalin and placebo groups (Fig. 5A) . These results suggest that regression to the mean occurred to some extent. The slopes of the regression lines were not significantly different (p = 0.73) between the pregabalin and placebo groups, and the intercept in the pregabalin group was significantly higher than that in the placebo group (p = 0.04) (Fig. 5A ). These findings establish that NPS was decreased to a greater extent by pregabalin than by the placebo and thus that pregabalin has a possible analgesic effect.
When the conditioned test stimulus was applied, the slopes of the regression lines were significantly different between the pregabalin and placebo groups (p = 0.0087). The initial NPS significantly affected the change in NPS in the pregabalin group (adj R 2 = 0.22, p = 0.012, y = 0.36x À 15.8) but not in the placebo group (p = 0.26) (Fig. 5B) . The change in NPS tended to be positive (initial NPS > post-NPS) in subjects with a higher initial NPS and negative (initial NPS < post-NPS) in subjects with lower initial NPS in the pregabalin group but not in the placebo group. Even though regression to the mean may have been present, regression to the mean could not be seen in the placebo group at this experiment. Rather, they indicate that pregabalin had a stronger analgesic effect in subjects who originally had low levels of endogenous analgesia.
Discussion
Effect of pregabalin
Effect of pregabalin on endogenous analgesia
Psychophysical paradigms such as CPM have established the importance of endogenous analgesia in CPM, conditioned pain modulation. Change in thresholds = pre-administration value À post-administration value. Change in CPM = post-CPM À initial CPM. The results represent the mean AE standard deviation. Figure 4 Effect of initial CPM on the change in CPM resulting from drug administration. A scatterplot and regression lines, using the change in CPM as the dependent variable and the initial CPM as the independent variable, are shown for each group. The regression slopes were significantly different between the pregabalin and placebo groups (p = 0.015). Initial CPM significantly influenced the change in CPM in pregabalin group but not placebo group (pregabalin group: adj R 2 = 0.51, p < 0.001, y = À0.54x + 2.98; placebo group: p = 0.56).
Higher and lower initial CPM indicate higher and lower original endogenous analgesia, respectively, and greater and lesser change in CPM indicate greater and lesser improvement of endogenous analgesia, respectively. Red circles and solid line; pregabalin group, blue squares and broken line; placebo group. CPM, conditioned pain modulation.
the development of chronic pain in recent decades (Yarnitsky, 2015) . Pregabalin is considered to exert its analgesic effect at least partly by endogenous analgesia through the noradrenergic pathway (Tanabe et al., 2005; Takeuchi et al., 2007) . To date, however, the relationship between pregabalin and endogenous analgesia has not been revealed in human studies.
Regarding the underlying mechanism, it was previously reported that the CPM paradigm provides analgesia in rats by increasing the noradrenaline level in the lumbar spinal cord, and that this analgesic effect was reduced by blockade of a 2 -adrenergic receptors or ablation of the noradrenergic pathway (Peters et al., 2014) . These findings suggest that the descending inhibitory noradrenergic pathway plays an important role in endogenous analgesia induced by the CPM paradigm.
Pregabalin and gabapentin specifically bind with high affinity to the same target, the a2d calcium channel (Taylor, 2009) , which is distributed in the brain and spinal cord. They both show analgesic efficacy for neuropathic pain, including reduction in pain scores and improvement of allodynia in diabetic neuropathy (Richter et al., 2005; Arezzo et al., 2008) , postherpetic neuropathy (Stacey et al., 2008) , and post-traumatic neuropathy (Van Seventer et al., 2010) . Hayashida et al. (2008) demonstrated that intravenously administered gabapentin increased the activity of noradrenergic neurons in the locus coeruleus and increased spinal noradrenaline release in both na€ ıve rats and rats subjected to spinal nerve ligation, a model of neuropathic pain. It was thus suggested that gabapentin acts in the locus coeruleus to activate the descending noradrenergic inhibitory system. Similarly, it has been reported that both pregabalin and gabapentin administered intracerebroventricularly or intraperitoneally had analgesic effects that were suppressed by the ablation of noradrenergic neurons (Tanabe et al., 2005; Takeuchi et al., 2007) . A human study also reported that gabapentin given preoperatively increased the noradrenalin concentration in the cerebrospinal fluid and decreased the amount of morphine consumption after surgery (Hayashida et al., 2007) . These studies collectively suggest that the analgesic effect of gabapentin and pregabalin is at least partly mediated by noradrenalin release induced by activation of the descending noradrenergic system, which as described above is one of the mechanisms underlying endogenous analgesia.
In the current study, we demonstrated that the initial CPM significantly affected the change in CPM in the pregabalin group but not in the placebo group, i.e. pregabalin increased the CPM in subjects with a lower initial CPM and decreased the CPM in subjects with a higher initial CPM. This result indicates that pregabalin improved endogenous analgesia in individuals with lower original endogenous analgesia, but the placebo did not. Furthermore, pregabalin provided a greater analgesic effect in subjects in whom the conditioning stimulus had a lower Figure 5 Effect of pregabalin in the test stimulus and conditioned test stimulus conditions. A scatterplot and regression lines, using the change in NPS as the dependent variable and the initial NPS as the independent variable, are shown for the test stimulus (A) and conditioned test stimulus (B). (A) Test stimulus: The slopes of the regression lines were not significantly different between the pregabalin and placebo groups (p = 0.73), and the intercept in the pregabalin group was significantly higher than that in the placebo group (p = 0.04); pregabalin decreased NPS to a greater extent than the placebo. (B) Conditioned test stimulus: The slopes of the regression lines were significantly different between the pregabalin and placebo groups (p = 0.0087). The initial NPS significantly affected the post-NPS in the pregabalin group (adj R 2 = 0.22, p = 0.012, y = 0.36x À 15.8) but not in the placebo group (p = 0.26). Pregabalin provided a stronger analgesic effect in subjects with higher initial NPS than in those with lower initial NPS. Red circles and solid line; pregabalin group, blue squares and broken line; placebo group. NPS, numerical pain scale.
analgesic effect. Taken together with the previous findings discussed above, our results suggest that pregabalin provides a stronger analgesic effect in individuals with lower endogenous analgesia by augmenting their endogenous analgesia. These findings could help to explain the selective clinical efficacy of pregabalin in chronic pain, as we expect that healthy individuals typically have sufficient endogenous analgesia to prevent hyperalgesia, whereas in patients with chronic pain, the endogenous analgesic machinery is compromised. Thus, we consider that pregabalin might 'repair' the compromised endogenous analgesia in patients with chronic pain, whereas it would not provide further benefit to the already-intact endogenous analgesia in healthy individuals.
Effect of pregabalin on excitatory pathways
Yarnitsky et al. proposed the idea that pain is modulated by the balance between the inhibitory and facilitatory systems, and that this balance differs depending on the individuals. CPM and temporary summation (TS) are considered to indicate the inhibitory and facilitatory balance (Yarnitsky et al., 2014) . For temporal summation, it is reported that in migraine patients, the increased temporal summation is related to a higher pain intensity during attacks as well as, more frequent attacks (WeissmanFogel et al., 2003) . Higher temporary summation as well as lower CPM are also reported in the painful knee of osteoarthritic patients than that reported in control (Arendt-Nielsen et al., 2010) . These evidences indicate the importance of both inhibitory and facilitatory systems in chronic pain. In the present study, we focused on the pain inhibitory system, such as endogenous analgesia, using CPM. Considering the importance of the facilitatory system of pain, it is desired to assess temporal summation as well as CPM in future studies.
Effect of pregabalin on anxiety
Pregabalin has clinical efficacy in the case of anxiety disorders. Although the present study included healthy subjects and to the best of our knowledge, drugs, including anti-anxiety drugs, have not been used commonly, the possibility that pregabalin affected the degree of anxiety cannot be excluded. It would be better to assess the volunteers' anxiety status in studies concerning pregabalin to accurately investigate its effect.
Pregabalin clearance
It was previously reported that pregabalin clearance is proportional to creatinine clearance (CLcr) up to a CLcr rate of approximately 100 mL/min and then becomes constant (Shoji et al., 2011) . The present trial included healthy subjects aged 20-42 years without renal disease. A review of aging biology and pharmacology (McLean and Le Couteur, 2004) suggested that in the absence of disease, GFR may not decrease as much as previously reported. In fact, a study on renal function (Adachi et al., 2001) showed that the CLcr in healthy subjects aged under 60 years was >100 mL/min. Taking into account these previous findings, we consider that the drug clearance likely did not have a major effect on the blood concentration of pregabalin in this study.
Conditioned pain modulation in chronic pain
Several studies have reported lower CPM in some chronic pain states (Nir and Yarnitsky, 2015) such as fibromyalgia (Kosek and Hansson, 1997; Julien et al., 2005) , chronic tension headache (Pielsticker et al., 2005; Sandrini et al., 2006) , migraine headache (Sandrini et al., 2006) , temporomandibular disorder (King et al., 2009) , and irritable bowel syndrome (King et al., 2009) , and a recent systematic review also indicated that CPM is impaired in patients with chronic pain (Lewis et al., 2012) . The reported reduction in CPM supports our hypothesis that insufficient endogenous analgesia is closely associated with the formation of some chronic pain states. Furthermore, it has been shown that preoperative CPM is a predictor of chronic postoperative pain in patients who receive thoracotomy surgery , which suggests a causative role for lower endogenous analgesia in the development of chronic pain. Selection of an appropriate treatment method in chronic pain patients is difficult because of the differences in etiology, severity, and characteristics among patients. Although drug therapy is a major method in chronic pain management, it takes time to find a suitable drug for each patient. Therefore, an indicator for drug selection is necessary. In this study, we showed that endogenous analgesia is augmented by pregabalin relative to a placebo in subjects with a lower original level of endogenous analgesia. This measurement of original endogenous analgesia using CPM may thus be a useful indicator for the use of pregabalin and other drugs in pain management.
We conducted this study with healthy subjects as a first step because the efficacy of pregabalin in endogenous analgesia was unclear. We also wanted to avoid conducting the CPM measurement in chronic pain patients until we confirmed its validity because it could be invasive for patients with hyperalgesia. The present findings will allow us to proceed to evaluation of drug effects on CPM in chronic pain patients, with the eventual goal of enhancing therapeutic outcomes by individually optimizing drug treatment based on predicted efficacy.
Limitations
Some limitations exist in this study. First, effects of gender and menstrual phase on CPM have been reported (Popescu et al., 2010; Rezaii et al., 2012) ; therefore, although these effects should have been controlled for by random assignment of subjects to the two groups, the possibility that the gender and menstrual phase of the subjects affected our results cannot be excluded. Second, because we randomly assigned subjects to each group, the initial CPM might not have been completely identical between the groups, and the difference in initial CPM magnitude between groups might have affected our results. Third, our study is limited with regard to the generalization of our results to actual clinical situations. In particular, drug efficacy should be evaluated not only by psychophysiological testing (e.g. CPM), but also by subjective evaluation (e.g. pain score or global impression). In the present study, we could not include subjective evaluations of pain relief because the study was conducted in healthy subjects who were not experiencing pain. Because it is uncertain whether our results will actually be applicable to clinical pain therapy, further studies should be conducted with chronic pain patients as noted above.
Conclusions
In the present study, we demonstrated that subjects with a lower initial CPM experienced greater CPM improvement when taking pregabalin. This result suggests that pregabalin acts at least partly by improving endogenous analgesia and introduces the possibility that the effect of pregabalin in chronic pain could be predicted by measuring CPM prior to administration.
